About this trial
According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
Ampicillin-sulbactam
DrugIf a patient meets dual criteria (presepsin \> 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.
Treatment groups
Trial outcomes
Primary outcomes
Infectious complications rate
Postoperative pneumonia, sepsis, wound infection, mediastinitis
Secondary outcomes
Total amount of complicated patients
Patients that suffer at least 1 complication in postoperative period
Mortality
In-hospital mortality rate
Length of hospital stay
Days spent in hospital since admission
Length of ICU stay
Hours in ICU after the surgery
Sponsors and contacts
Click on the lead sponsor to view all of their trials.